Review reveals molecular and clinical strategies for risk stratification in intraductal papillary mucinous neoplasms, highlighting paths to improve early pancreatic cancer detection.
Key Points
To synthesize histopathological, molecular, and clinical evidence regarding intraductal papillary mucinous neoplasms and evaluate biomarker-driven approaches for personalized risk stratification.
Reviewed diagnostic and management strategies across anatomical subtypes of intraductal papillary mucinous neoplasms (main duct, branch duct, and mixed type).
Assessed the utility of advanced abdominal imaging, endoscopic ultrasound, and emerging molecular biomarkers from cyst fluid for detecting malignant transformation.
Characterized main duct, branch duct, and mixed-type lesions, noting that location significantly influences the baseline probability of malignant progression.
Identified endoscopic ultrasound and cystic fluid analysis as critical secondary interventions for assessing malignancy risk in asymptomatic precursor lesions.
Highlighted that integrating molecular alterations and novel fluid biomarkers with standard imaging improves precision in predicting invasive pancreatic cancer compared to conventional guideline criteria alone.